Available Jakinibs for the management of moderate to severe ulcerative colitis include non-selective tofacitinib (FDA) and selective JAK1 inhibitors filgotinib (EMA) and upadacitinib (FDA). The gene discussed is JAK1; the disease is ulcerative colitis.